Sinusoidal Obstruction Syndrome
12
2
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
8%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Defibrotide Dose-escalation for SOS Post-HSCT
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic HSCT
Ultrasound Elastography to Predict Development of SOS
Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study
Liver Stiffness Measurement Predicts VOD/SOS Development (ELASTOVOD ITALIAN MULTICENTRIC STUDY)
5-day Defibrotide Treatment for Hepatic SOS/VOD
Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants